Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2024.2394124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Natalia Espinola und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argenti…. Hauptthemen laut MEDLINE: Budgets, Private Sector, Drug Costs, Severity of Illness Index. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: AbbVie.
Abstract (Originalsprache)
OBJECTIVES: Our study assessed the budget impact and cost per responder of upadacitinib15mg and 30 mg for moderate to severe atopic dermatitis (MS-AD) treatment from social security and private health sector perspective in Argentina. METHODS: A budget impact model was adapted to depict clinical and economic aspects of treatment over a 5-years horizon time. Scenario analyses and deterministic sensitivity analyses were performed. A 16-weeks cost per responder model was adapted based on a network meta-analysis. Primary analyses assessed the cost per Eczema Area and Severity Index 50, 75 and 90 at week 16. RESULTS: The inclusion of upadacitinib 15 mg and 30 mg in the biological treatment mix for MS-AD was associated with an average budget saving per-member per-month ofU$S0.062 (social security) and U$S0.064 (private sector). Percentage of patients with access to treatment, acquisition cost of upadacitinib 30 mg and prevalence of MS-AD were the most influential parameters in the budget impact results. At week 16, upadacitinib 30 mg was associated with the lowest number needed to treat and the lowest cost per responder for all outcomes. CONCLUSION: The introduction of upadacitinib in MS-AD treatment was associated with modest savings for the social security and private payer budget in Argentina.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
- Centre for Health Economics (CHE), Alcuin 'A' Block, University of York, York, UK.
- Dermatology Department, Hospital Alemán, Buenos Aires, Argentina.
- Market Access Department, AbbVie, Buenos Aires, Argentina.
- Medical Department, AbbVie, Buenos Aires, Argentina.
- Center for Research in Epidemiology and Public Health, National Scientific and Technical Research Council, Buenos Aires, Argentina.
ORCID-Profile: Federico Rodríguez Cairoli, Carlos Rojas-Roque
Förderung
- AbbVie
Zitieren
APA
Espinola, N., Rodríguez Cairoli, F., Rojas-Roque, C., Luna, P. C., Kanevsky, D., Migliazza, V., & Pichon-Riviere, A. (2025). Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2394124
Vancouver
Espinola N, Rodríguez Cairoli F, Rojas-Roque C, Luna PC, Kanevsky D, Migliazza V, et al. Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2024.2394124
BibTeX
@article{Espinola2025,
author = {Espinola, Natalia and Rodríguez Cairoli, Federico and Rojas-Roque, Carlos and Luna, Paula Carolina and Kanevsky, Diego and Migliazza, Valeria and Pichon-Riviere, Andrés},
title = {Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2024.2394124}
}
EUVIMED